Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bai Jin Pill (also known as Baijin Wan) is a traditional Chinese medicine (TCM) formula developed and manufactured by Jinsheng Da Ren Tang (Tianjin Pharmaceutical Da Ren Tang Group). It is composed of two primary active ingredients: Yujin (*Curcuma aromatica* or *Curcuma wenyujin*) and Alumen (alum). Bai Jin Pill is traditionally used to clear phlegm, open the sensory orifices, clear the heart, and calm the spirit. It is approved in China for the treatment of phlegm-qi obstruction, epilepsy, mania, sudden collapse, and spitting of saliva or froth. Modern pharmacological research indicates that curcumin, a key active component of Yujin, modulates receptor-type tyrosine-protein phosphatase zeta (PTPRZ1) activity, thereby regulating neuroinflammation and providing neuroprotective effects in epilepsy and associated cognitive dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bai Jin Pill.